Rapid Spread and Control of Multidrug-Resistant Gram-Negative Bacteria in COVID-19 Patient Care Units

Ashka Patel, Michele Emerick, Marie K Cabunoc, Michelle H Williams, Michael Anne Preas, Gregory Schrank, Ronald Rabinowitz, Paul Luethy, J Kristie Johnson, Surbhi Leekha, Ashka Patel, Michele Emerick, Marie K Cabunoc, Michelle H Williams, Michael Anne Preas, Gregory Schrank, Ronald Rabinowitz, Paul Luethy, J Kristie Johnson, Surbhi Leekha

Abstract

We describe rapid spread of multidrug-resistant gram-negative bacteria among patients in dedicated coronavirus disease care units in a hospital in Maryland, USA, during May-June 2020. Critical illness, high antibiotic use, double occupancy of single rooms, and modified infection prevention practices were key contributing factors. Surveillance culturing aided in outbreak recognition and control.

Keywords: COVID-19; MDR; Maryland; SARS-CoV-2; United States; antimicrobial resistance; bacteria; bacterial infections; coronavirus disease; gram-negative; multidrug resistant; outbreak; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.

Figures

Figure
Figure
Incidence of patients with a clinical or surveillance culture-positive result indicating MDR or cefepime-resistant Escherichia coli, MDR Acinetobacter baumannii, or MDR Pseudomonas aeruginosa >48 hours after admission to a hospital in Maryland, USA, by week, March 1–July 31, 2020. A) Overall hospitalwide incidence (118 total cases, with 98 positive cultures belonging to outbreak units). Narrow white bars represent the number of surveillance cultures obtained during the outbreak and shaded bars show positive cultures by organism. Arrows show timing of relevant events for transmission and control. B) Incidence of outbreak cases (n = 98) stratified by the 3 units affected by the outbreak. Organisms nonsusceptible to >2 of piperacillin/tazobactam, cefepime, or carbapenem are considered MDR. Patients are included for the first positive culture per organism and therefore might be included more than once. MDR, multidrug-resistant.

References

    1. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75:1681–4. 10.1093/jac/dkaa194
    1. Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021;42:84–8. 10.1017/ice.2020.368
    1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). 2020. [cited 2020 Aug 20].
    1. Hill JT, Tran K-DT, Barton KL, Labreche MJ, Sharp SE. Evaluation of the nanosphere Verigene BC-GN assay for direct identification of gram-negative bacilli and antibiotic resistance markers from positive blood cultures and potential impact for more-rapid antibiotic interventions. J Clin Microbiol. 2014;52:3805–7. 10.1128/JCM.01537-14
    1. Donà D, Di Chiara C, Sharland M. Multi-drug-resistant infections in the COVID-19 era: a framework for considering the potential impact. J Hosp Infect. 2020;106:198–9. 10.1016/j.jhin.2020.05.020
    1. Kaier K, Mutters NT, Frank U. Bed occupancy rates and hospital-acquired infections—should beds be kept empty? Clin Microbiol Infect. 2012;18:941–5. 10.1111/j.1469-0691.2012.03956.x
    1. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98:442–442A. 10.2471/BLT.20.268573
    1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71:2459–68.
    1. Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al.; EPIC III Investigators. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:1478–87. 10.1001/jama.2020.2717
    1. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, et al. Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020. MMWR Morb Mortal Wkly Rep. 2021;70:56–7. 10.15585/mmwr.mm7002e3

Source: PubMed

3
Subskrybuj